The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study.
Despite a marked reduction in cardiovascular morbidity and mortality , treated hypertensive patients remain at increased risk of coronary artery disease and its complications compared with untreated normotensive subjects . Mild hypertension is often associated with other , usually chronic , diseases . The failure of first-line antihypertensive therapy to deal adequately with concomitant disease and associated therapy might account for the poor improvement in the cardiovascular prognosis . This possibility has been addressed in an ongoing trial of novel design , the Perindopril Therapeutic Safety Study , a multicenter , double-blind , r and omized and placebo-controlled trial to determine the safety , efficacy , and interaction of angiotensin-converting enzyme ( ACE ) inhibition with eight of the most common concomitant diseases and their therapies . A total of 480 male and female patients ( 60 per disease group ) aged 30 - 70 years , with a diastolic pressure of 90 - 104 mm Hg , were included after a 3-week placebo run-in if they satisfied st and ard criteria for any of the following : hyperlipidemia , type II diabetes , ischemic heart disease , cardiac arrhythmia , peripheral arterial disease , nephropathy with proteinuria , chronic obstructive lung disease , or rheumatoid arthritis . Of these , 460 patients have completed the 6-week double-blind phase ( comprising two assessment s , at 3 and 6 weeks ) , and are currently undergoing assessment s every 3 months over a 1-year follow-up period . The end points include the incidence of progression or improvement in concomitant disease , the incidence of positive or negative interaction between ACE inhibition and concomitant therapy , change in blood pressure , adverse biochemical and hemodynamic reactions , self-reported side effects , and quality of life indices . Interim results for the 6-week double blind phase will shortly be available . However , the desirability and feasibility of conducting a study according to this novel design have already been proved
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .